Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

AM, Lincoff; JA, Bittl; RA, Harrington; F, Feit; NS, Kleiman; JD, Jackman; IJ, Sarembock; DJ, Cohen; D, Spriggs; R, Ebrahimi; G, Keren; J, Carr; EA, Cohen; A, Betriu; W, Desmet; DJ, Kereiakes; W, Rutsch; RG, Wilcox; Feyter PJ, de; A, Vahanian; EJ, Topol

doi:10.1001/jama.289.7.853

Public

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Shared by NobleBlocks on Feb 1, 2003 • 12:00 AM UTC

Authors:

Lincoff AM

Bittl JA

Harrington RA

Abstract

Context The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI).Objective To determine the efficacy of bivalirudin...

Discussions